Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ulixertinib in Recurrent MAPK-Activated Gliomas
NCT05804227Phase 1Recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Apr 2023
- Primary completion
- Sep 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of ulixertinib in glioma (2 arms), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Incidence of Adverse Events at 1 year, Ulixertinib tumor concentration and tumor/plasma ratio at 14 days and 1 more. Started Apr 2023; status: recruiting.
02
Drugs
ulixertinib
03
Conditions
glioma
Beyond the preview
Go deeper on NCT05804227.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05804227.